V
Véronique Girre
Researcher at Curie Institute
Publications - 34
Citations - 1652
Véronique Girre is an academic researcher from Curie Institute. The author has contributed to research in topics: Breast cancer & Geriatric oncology. The author has an hindex of 16, co-authored 34 publications receiving 1504 citations. Previous affiliations of Véronique Girre include La Roche College & Jewish General Hospital.
Papers
More filters
Journal ArticleDOI
Management of breast cancer in elderly individuals: recommendations of the International Society of Geriatric Oncology
Hans Wildiers,Ian Kunkler,Laura Biganzoli,Jacques Fracheboud,George Vlastos,Chantal Bernard-Marty,Arti Hurria,Martine Extermann,Véronique Girre,Etienne Brain,Riccardo A. Audisio,Harry Bartelink,Mary B Barton,Sharon H. Giordano,Hyman B. Muss,Matti Aapro +15 more
TL;DR: The available evidence was reviewed and synthesised to provide consensus recommendations regarding the care of breast cancer in older adults and recommendations are given on the topics of screening, surgery, radiotherapy, (neo)adjuvant hormone treatment and chemotherapy, and metastatic disease.
Journal ArticleDOI
Use of Geriatric Assessment for Older Adults in the Oncology Setting: A Systematic Review
TL;DR: Geriatric assessment in the oncology setting is feasible, and some domains are associated with adverse outcomes, however, there is limited evidence that geriatric assessment impacted treatment decision making.
Journal ArticleDOI
Does a Geriatric Oncology Consultation Modify the Cancer Treatment Plan for Elderly Patients
Véronique Girre,Marie-Christine Falcou,Mathilde Gisselbrecht,Geneviève Gridel,Véronique Mosseri,Carole Bouleuc,Rollon Poinsot,Lionel Vedrine,Liliane Ollivier,Valérie Garabige,Jean-Yves Pierga,Véronique Diéras,Laurent Mignot +12 more
TL;DR: The geriatric oncology consultation led to a modification of the cancer treatment plan in more than one third of cases and further studies are needed to determine whether these modifications improve the outcome of these older patients.
Journal ArticleDOI
Phase I evaluation of seliciclib (R-roscovitine), a novel oral cyclin-dependent kinase inhibitor, in patients with advanced malignancies
Christophe Le Tourneau,Sandrine Faivre,Valérie Laurence,Catherine Delbaldo,Karina Vera,Véronique Girre,Judy H. Chiao,Sian Armour,Sheelagh Frame,Simon Green,Athos Gianella-Borradori,Véronique Diéras,Eric Raymond +12 more
TL;DR: AIM Phase I study of seliciclib (CYC202, R-roscovitine), an inhibitor of cyclin-dependent kinases 2, 7 and 9, causing cell cycle changes and apoptosis in cancer cells, defining the toxicity profile, the maximum tolerated dose (MTD), the recommended phase II dose (RD) and the main pharmacokinetic and pharmacodynamic parameters of oral se liciclib.
Journal ArticleDOI
Survival of breast cancer patients with meningeal carcinomatosis
Hélène Gauthier,M.N. Guilhaume,François-Clément Bidard,J-Y Pierga,J-Y Pierga,Véronique Girre,Paul Cottu,Valérie Laurence,Alain Livartowski,Laurent Mignot,Véronique Diéras +10 more
TL;DR: A prognostic score is proposed in order to define three distinct groups of prognosis in patients diagnosed with breast cancer MC and treated in single institution by a high-dose intrathecal methotrexate (MTX) regimen.